VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

World Sleep 2022 | Advances in upper airway stimulation for OSA: Genio

Nico de Vries, MD, PhD, OLVG West Hospital, Amsterdam, The Netherlands, discusses the benefits of upper airway stimulation in obstructive sleep apnea (OSA). This video compares the Inspire Upper Airway Stimulation (UAS) system with its main competitor Genio by Nyxoah. Both systems use hypoglossal nerve stimulation technology to relieve symptoms of OSA. Genio is minimally invasive, wireless, MRI safe, and does not require drug-induced sleep endoscopy (DISE). Nyxoah’s UAS device obtained CE mark certification following success in the BLAST OSA (NCT03048604) feasibility study. Long-term efficacy and safety are currently being evaluated in the ELiSA (NCT04031040) five-year follow-up study. Genio received breakthrough device designation from the FDA in September 2021, supported by data from the BETTER SLEEP (NCT03763682) trial, aimed at addressing the long-term safety and performance in adult OSA patients with and without complete concentric collapse (CCC). Based on provisional results from the ongoing DREAM (NCT03868618) interventional clinical trial, full FDA approval is expected. This interview took place at the World Sleep Congress 2022 in Rome, Italy.